Dual carrier immunogenic construct

Details Dual carrier immunogenic construct Dual carrier immunogenic construct

1995-06-06

1999-09-21

Housel, James C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

42419711, 4242011, 4242031, 4242801, 4242441, 5361231, 530403, 530412, 530806, A61K 39385

Patent

active

059550791

ABSTRACT:
A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, treatment, and prevention of diseases.

REFERENCES:
patent: 4169137 (1979-09-01), Hirschfeld et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4415552 (1983-11-01), Diener et al.
patent: 4434150 (1984-02-01), Azad et al.
patent: 4619828 (1986-10-01), Gordon
patent: 4644059 (1987-02-01), Gordon
patent: 4703039 (1987-10-01), Hawiger et al.
patent: 4713240 (1987-12-01), Wilkins et al.
patent: 4748111 (1988-05-01), Dattagupta et al.
patent: 4769237 (1988-09-01), Bittle et al.
patent: 4780312 (1988-10-01), Talwar
patent: 4824775 (1989-04-01), Dattagupta et al.
patent: 4830852 (1989-05-01), Marburg et al.
patent: 4863729 (1989-09-01), Zuckerkandl
patent: 4894229 (1990-01-01), Polson et al.
patent: 5085862 (1992-02-01), Klein et al.
patent: 5126131 (1992-06-01), Dintzis et al.
patent: 5153312 (1992-10-01), Porro
patent: 5370871 (1994-12-01), Dintzis et al.
Dintzis and Dintzis, "Profound Specific Suppression by Antigen of Persist IgM, IgG, and IgE Antibody Production", Proc. Natl'l Acad Sci, USA, 89:1113-1117 (Feb. 1992).
Dintzis et al., Fed. Am. Soc. Exp. Biol. 46(3):777 Abstract (1987).
Berzofsky et al., "Protein Antigenic Structures Recognized by T Cells: Potential Applications to Vaccine Design," Immunol. Rev. 98:9-52 (1987).
Milich et al., "Synthetic peptides: prospects for vaccine development," Immunol. 2 (5) :307-315 (1990).
Roitt I.M., Essential Immunology, Blackwell Scientific Publications, Oxford, p. 55 (1988).
Roitt et al., Immunology, C.V. Mosby Co., St. Louis, p. 2 of glossary (1985).
Schneerson et al., "Serum Antibody Responses of Juvenile and Infant Rhesus Monkey Injected with Haemophilus influenzae Type b and Pneumococcus Type 6A Capsular Polysaccharide-Protein Conjugates," Infect. Immunol. 45(3) :582-591 (1984).
Beuvery et al., "Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate," J. Infect. 6:247-255 (1983).
Barington et al., "Non-Epitope-Specific Suppression of the Antibody Response to Haemophilus influenzae Type b Conjugate Vaccines by Preimmunization with Vaccine Components," Infect. & Immun. 61(2):432-438 (1993).
Barington et al. "Influence of Prevaccination Immunity on the Human B-Lymphocyte Response to a Haemophilus influenzae Type b Conjugate Vaccine," Infect & Immun. 59(3):1057-1064 (1991).
Clemens et al., "Impact of Haemophilus influenzae Type b Polysaccharide-Tetanus Protein Conjugate Vaccine on Responses to Concurrently Administered Diphtheria-Tetanus-Pertussis Vaccine," JAMA 267(5):673-673 (1992).
Greenberg et al., "Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants," J. Infect. Dis. 170:76-81 (1994).
Peeters et al., "A Comparative Study of the Immunogenicity of Pneumococcal Type 4 Polysaccharide and Oligosaccharide Tetanus Toxid Conjugates in Adult Mice," J. Immunol. 146:4308-4314 (1992).
Physicians' Desk Reference, HibTiter.RTM., pp. 1162-1163 (1994).
Centers for Disease Control and Prevention, "FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children," JAMA 269(18):2359 (1993).
Recommended Childhood Immunization Schedule United States, for Jan. -Jun. 1996.
Seppala et al., "Effect of Molecular Weight of the Carbohydrate and Comparison of Two Modes of Coupling," The Journal of Immunology 143:1259-1264 (1989).
Ahmad et al., The Journal of Immunology, 136:1223-1226, "Restoration of In Vitro Responsiveness of XID B Cells to TNP-Ficoll by 8-Mercaptoguanosine," (1986).
Anderson et al., The Journal of Immunology, 142:2464-2468, "Effect of Oligosaccharide Chain Length, Exposed Terminal Group, and Hapten Loading on the Antibody Response of Human Adults and Infants to Vaccines Consisting of Haemophilus Influenzae Type b Capsular Antigen Uniterminally Coupled To The Diphtheria Protein CRM197" (1989).
Baltz et al., "Down Regulation In B Lymphocytes: Low Dose Signals," Eur. J. Immunol. 7:218-222 (1977).
Boslego et al., "Gonorrhea Vaccines," Vaccines & Immunology, pp. 211-224, Cryz, Jr., (ed.) Pergamon Press, New York, 1991.
Brunswick et al., The Journal of Immunology, 140:3364-3372, "Picogram Quantities of Anti-Ig Antibodies Coupled to Dextran Induce B Cell Proliferation," (1988).
Butcher, "Mechanisms of Immunity To Malaria And The Possibilies Of A Blood-Stage Vaccine: A Critical Appraisal," Parisitology 98:315-327, (1989).
Dancey et al., The Journal of Immunology, 122:638-642, "Immunogenicity of Liposomal Model Membranes Sensitized with Dinitrophenylated Phosphatidylethanolamine Derivatives Containing Different Length Spacers," (1979).
Dick et al., "Glycoconjugates of Bacterial Carbohydrate Antigens," Contributions to Microbiology and Immunology, Conjugate Vaccines, 10:48-114, Cruse J. M., Lewis R. E. (eds), (1989).
Dintzis et al., The Journal of Immunology, 143:1239-1244, "The Immunogenicity of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence," (1989).
Geerligs, et al., Journal of Immunological Methods, "The Influence of pH and Ionic Strength on the Coating of Peptides of Herpes Simplex Virus Type 1 in an Enzyme-Lined Immunosorbent Assay," vol. 106, pp. 239-244 (1988).
Hosokawa, "Studies on B-Cell Memory," Immunology, 38:291-299 (1979).
Inman, "Thymus-Independent Antigens: The Preparation of Covalent, Hapten-Ficoll Conjugates," Journal of Immunology, 114(2) : 704-709 (1975).
Mitani et al., Infection and Immunity, "Immunoglobulin E--Suppressing and Immunoglobulin G--Enhancing Tetanus Toxoid Prepared by Conjugation with Pullulan," vol. 36, No. 3, pp. 971-976 (1982).
Mosier et al., The Journal of Experimental Medicine, 139:1354-1360, "Cellular Requirements for the Primary In Vitro Antibody Response to DNP-Ficoll," (1974).
Mosier et al., The Journal of Immunology, 119:1874-1878, "The Ontogeny of Thymic Independent Antibody Responses In Vitro in Normal Mice and Mice With an X-Linked B Cell Defect," (1977).
Mond, Immunological Reviews, 64:99-115, "Use of the T Lymphocyte Regulated Type 2 Antigens for the Analysis of Responsiveness of Lyb5 and Lyb5 B Lymphocytes to T Lymphocyte Derived Factors," (1982).
Mond et al., The Journal of Immunology, 123:239-245, "Analysis of B Cell Activation Requirements with TNP-Conjugated Polyacrylamide Beads," (1979).
Patarroyo et al., "Induction Of Protective Immunity Against Experimental Infection With Malaria Using Synthetic Peptides," Letters to Nature, 328:629-632, (1987).
Tadakuma et al., "Effect of Lipid A Incorporation on Characterization of Lipsomal Model Membranes as Thymus-Independent Type 1 or Type 2 Immunogens," Journal of Immunology, 128-1:206-210 (1982).
Watanabe et al., "Specific Suppression of Hybridoma Immunoglobulin Secretion by Hapten-Conjugated Mouse IgG: A Model of B-Cell Tolerance," Cellular Immunology, 79:345-357 (1983).
Yaffe, et al., Journal of Immunology, "Analysis of the B Cell Subpopulations Influenced by Allogeneic Effect Factor I. MHC Restricted Enhancement of B Cell Responses to Thymic-Independent Antigens, Types 1 and 2, in Normal and CBA/N Mice," vol. 130, No. 2, pp. 632-635 (1983).
Kallings et al., "Placebo Controlled Trial of Two Acellular Pertussis Vaccines in Sweden--Protective Efficacy and Adverse Effects," The Lancet, 955-960, Apr. 30, 1988.

Affiliated with

Also associated with

Rating

Dual carrier immunogenic construct does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dual carrier immunogenic construct, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual carrier immunogenic construct will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-77604